Therapy Area topics
Cardiovascular
Bayer faces an uphill fight with finerenone
Pivotal data on finerenone might see it approved, but competing in the market will be trickier.
Primary omecamtiv win is not enough
A theoretical pivotal trial success fails to back omecamtiv’s commercial promise and leaves Amgen’s pipeline in dire straits.
Bridgebio U-turn shows how money can be made twice over
The company becomes the third in two months to buy back a division it had spun out just a few years earlier.
Central Nervous System
Roche buys into Prothena... kind of
The Swiss group moves to start a further trial of prasinezumab, but this will not be phase III.
Diabetes
Lilly swerves the worst case for its Covid-19 antibody
Bamlanivimab bucks could help Lilly bounce back from a soft third quarter, but diabetes is the big focus.
Bayer faces an uphill fight with finerenone
Pivotal data on finerenone might see it approved, but competing in the market will be trickier.
The window of opportunity opens wider for Ascendis
With the previous incumbent withdrawn from the market Ascendis hails a new hormone replacement for hypoparathyroidism.
Digital Health
FDA tightens up digital health oversight
Software-enabled medical devices pose unique challenges to regulators, and the US agency is getting serious about meeting them.
Boehringer hopes schizophrenia apps will Click into place
Licensing deal could enable bundling of antipsychotics with management technology.
Teladoc bets $18.5bn that Covid-19 will change the world for good
The purchase of Livongo is the richest healthcare deal this year, but questions about reimbursement, competition and profitability remain.
Oncology
Exact chases its dream with $1.7bn Thrive deal
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
Triple meeting – Mirati gets an edge over Amgen
Mirati’s Kras inhibitor looks better than Amgen’s on efficacy, but toxicity worries prevent a knockout punch.
Triple meeting – the point of turning to TPX-0022
The first look at Turning Point’s TPX-0022 shows signs of activity beyond cMet inhibitors’ proven use in lung cancer.
Respiratory
Ionis joins the inhaled cystic fibrosis therapy race
Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.
Various
Go or no go? Vaccine panel upstages US approval decisions
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Clinical data focus for the smallest players
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
